# Junta clínica — PT-pseudo_c39e94a13920 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c39e94a13920",
  "pid": "PT-pseudo_c39e94a13920",
  "task": 1,
  "psa": 12.4,
  "age": 67,
  "months": 3,
  "pirads": "3",
  "psad": 0.08,
  "psav": 1.58,
  "psap": 11.3,
  "vol": 149.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.58010316,
  "medhx": "Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "atorvastatin, rosuvastatin",
  "notes": "PSA 12.4 ng/mL. PI-RADS 3. PSAD 0.08. Prostate volume 149 mL. csPCa 0.58.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Chronic kidney disease",
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "91 kg",
    "height": "178 cm",
    "bmi": "28.7",
    "bp": "128/89 mmHg",
    "hr": "70 bpm",
    "smoking": "Ex-smoker (19 pack-yr, quit 2016)",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "03 Jan 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical review sought due to sustained PSA elevation and a previously positive biopsy result."
    },
    {
      "s": "History",
      "t": "A 67-year-old married graphic designer residing with his partner, who receives weekly visits from his adult children, presents for this assessment. Initial symptoms included mild lower urinary tract complaints (IPSS 7/35), prompting surveillance that began in mid-2023. His medical background encompasses hypercholesterolaemia treated with atorvastatin and rosuvastatin, stage 3 chronic kidney disease (creatinine 166 umol/L, eGFR <60), and knee osteoarthritis. He ceased smoking in 2016 after accumulating 19 pack-years and sustains a fitness regimen of 5 km runs three times weekly, alongside a modest alcohol intake of four units per week. Recent interventions include a six-session physiotherapy course for mechanical lower back pain and routine endocrinology thyroid screening, both remaining clinically stable. While he reports occasional fatigue, he attributes this to visual impairment requiring large-print materials and expresses no particular anxiety regarding his prostate cancer history."
    },
    {
      "s": "Physical examination",
      "t": "DRE — prostate: symmetrically enlarged, smooth, firm; no palpable nodules or asymmetry detected. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are normal. Peripheral oedema and lymphadenopathy are absent."
    }
  ],
  "occupation": "graphic designer",
  "marital": "Married",
  "living": "Lives with partner; adult children visit weekly",
  "next_of_kin": "Long-time friend (no close family)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "4 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c39e94a13920
Task: 1

Encounter: Urology - outpatient on 03 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 12.4 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.58 ng/mL/yr
  - Prior PSA: 11.3 ng/mL
  - Prostate volume: 149.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.58010316 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: atorvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 12.4 ng/mL. PI-RADS 3. PSAD 0.08. Prostate volume 149 mL. csPCa 0.58.

Vitals: weight 91 kg, height 178 cm, BMI 28.7, BP 128/89 mmHg, HR 70 bpm. Smoking: Ex-smoker (19 pack-yr, quit 2016).

Chief complaint: Clinical review sought due to sustained PSA elevation and a previously positive biopsy result.

History: A 67-year-old married graphic designer residing with his partner, who receives weekly visits from his adult children, presents for this assessment. Initial symptoms included mild lower urinary tract complaints (IPSS 7/35), prompting surveillance that began in mid-2023. His medical background encompasses hypercholesterolaemia treated with atorvastatin and rosuvastatin, stage 3 chronic kidney disease (creatinine 166 umol/L, eGFR <60), and knee osteoarthritis. He ceased smoking in 2016 after accumulating 19 pack-years and sustains a fitness regimen of 5 km runs three times weekly, alongside a modest alcohol intake of four units per week. Recent interventions include a six-session physiotherapy course for mechanical lower back pain and routine endocrinology thyroid screening, both remaining clinically stable. While he reports occasional fatigue, he attributes this to visual impairment requiring large-print materials and expresses no particular anxiety regarding his prostate cancer history.

Physical examination: DRE — prostate: symmetrically enlarged, smooth, firm; no palpable nodules or asymmetry detected. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are normal. Peripheral oedema and lymphadenopathy are absent.

Patient info: graphic designer; Married; Lives with partner; adult children visit weekly.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 4 units / week; exercise Running 3x/week, 5 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Endocrine — thyroid screening.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.53
  uncertainty  +/- 0.16 epistemic (95% band 0.21-0.84); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.07: PI-RADS 3, PSA 7.7, PSAD 0.11, age 64, DRE Normal -> DEFER (borderline). He wrote: "Low risk PC with PSA <10. No red flags on biopsy or MRI, reasonably low PSA density. MRI finding minor and probably penetrated by systematic biopsy core (peripheral zone…"
  2. distance 2.08: PI-RADS 3, PSA 6.0, PSAD 0.13, age 58, DRE Normal -> DEFER (borderline). He wrote: "Need to know earlier MRI results. If stabile P3 lesion, no biopsy."
  3. distance 2.09: PI-RADS 4, PSA 8.4, PSAD 0.1, age 63, DRE Normal -> BIOPSY (uncertain). He wrote: "Patient on Active surveillance. Initial ISUP and MRI is needed."

PRECEDENT: DEFER (weighted vote 0.26 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the use of MRI to guide biopsy and the role of PI-RADS scores. "A stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15." This suggests that a stable MRI and low PSA density might exclude a repeat biopsy.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of biopsy because the guideline suggests that a stable MRI and low PSA density might exclude a repeat biopsy. EXPERT-COHORT, the finding that the panel does not determine the decision is precisely what the guideline suggests is insufficient, as the guideline provides risk-adapted thresholds that should be applied.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: the guideline does not provide a specific threshold for PSA velocity in this context, but the trend is a factor in risk stratification.
laboratory_results - the PSA density: the guideline suggests a PSA-D < 0.15ng/mL/cc might exclude a repeat biopsy if the MRI is stable.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on the documented grade of the prior biopsy and the PSA density, as the guideline suggests these factors might exclude a repeat biopsy.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Determine the PSA velocity as a factor in risk stratification.
  previous_notes (get_previous_notes) -> Determine the documented grade of the prior biopsy and surveillance status.
  laboratory_results (get_lab_results) -> Determine the PSA density value.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy?
  Q2. Does the MRI report indicate if the lesion is compared against an earlier study?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Is the PSA density less than 0.15 ng/mL/cc?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "A focal area is noted in the right peripheral zone at the mid-gland level, spanning roughly 14 x 11 x 10 mm."

psa_trend
The PSA velocity as a factor in risk stratification: PSA rose from 2.2 (Aug 2023) to 12.4 (Jan 2025), with the steepest rise between Aug 2024 (8.0 ng/mL) and Jan 2025 (12.4 ng/mL).

previous_notes
PRIOR GRADE: not recorded
BIOPSY SESSIONS: not recorded
SURVEILLANCE: surveillance that began in mid-2023
TREATMENT: none recorded

laboratory_results
The PSA density value: PSA density is "0.08 ng/mL/mL".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already established the context of the prior biopsy status.

WHAT THIS SUPPORTS
findings that argue FOR sampling this patient now:
PSA velocity shows a significant recent rise, indicating progression.
The prior biopsy result is positive, which necessitates re-evaluation.

findings that argue AGAINST sampling this patient now:
The MRI shows a PI-RADS 3 lesion, which is equivocal, and the PSA density is low (0.08 ng/mL/mL), which aligns with EAU guidance suggesting exclusion criteria.

WHERE THIS LEANS
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 12.40 ng/mL over 5 points spanning 17 months; velocity +7.21 ng/mL per year; doubling time about 7 months.
PROJECTION at 6 months: 21.9 ng/mL, conformal 95% band 6.3-76.4.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.61
  uncertainty  +/- 0.16 epistemic (95% band 0.30-0.92), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.53  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.61  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.26  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.58 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: borderline. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have addressed the moderator's questions, as the `previous_notes` state the prior grade is "not recorded," and the `radiology_report` indicates a comparison ("COMPARISON: new").

ALIGNMENT WITH THE PANEL
The panel protocol concluded BIOPSY based on a weighted vote of the experts, despite the lack of a documented prior grade in the opened documents. The retrieved findings, specifically the rising PSA velocity and low PSA density, argued for deferral, which conflicts with the panel's decision.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy? This question remains unanswered, as the `previous_notes` explicitly state the prior grade is "not recorded."
Q2. Does the MRI report indicate if the lesion is compared against an earlier study? The `radiology_report` indicates "COMPARISON: new," answering this question.

WHAT CARRIES WEIGHT, AND WHY
The PSA velocity (rising from 2.2 to 12.4 ng/mL) is highly relevant as it suggests progression, arguing for biopsy. Conversely, the low PSA density (0.08 ng/mL/mL) aligns with EAU guidance suggesting exclusion criteria, arguing against biopsy.

MY SUGGESTION TO THE CHAIR
Given that the critical factor—the documented prior biopsy grade—is missing, and the guideline suggests low PSA density might exclude biopsy if the MRI is stable, I suggest deferral pending clarification on the prior biopsy result.

VERDICT: not-ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

67y male, PSA 12.4, PSAD 0.08, PI-RADS 3, on surveillance after prior positive biopsy. Prior ISUP grade not recorded, but rising PSA and new lesion size warrant sampling. Low PSAD argues against immediate intervention, but lack of prior grade necessitates biopsy for definitive management. Consider delaying for one year if patient prefers.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
